Neo-adjuvant chemotherapy (NAC) is administered in breast cancer treatment for downstaging of disease. Here, we determined the impact of response to NAC on breast reconstruction uptake. A prospective NAC and mastectomy database with or without reconstruction were reviewed with IRB approval. Univariable analyses were conducted using Kruskal-Wallis or Fisher's exact tests. Multivariable logistic regression was used to adjust for potential confounders. We identified 271 patients with unilateral breast cancer receiving NAC and either unilateral or bilateral mastectomy from 9/2013 to 5/2016. Seventy patients (25.8%) had a pCR to NAC. One hundred and seventy-five patients (64.6%) had immediate reconstruction (IR), and 96 had no IR. On univariable analysis, younger age (P < .001), lower T-stage at presentation (P < .001), bilateral versus unilateral mastectomy (P<.001) and HR-negative tumor subtype (P = .006) were significantly associated with higher IR rates. On multivariable analysis, pCR (P = .792) and tumor subtype (P = 0.061) were not significantly associated with IR; T-stage was significantly associated with IR (P < .001), such that patients with T4 tumors at presentation had lower odds of IR (OR 0.10, 95% CI 0.02-0.50), even when accounting for response to NAC. One hundred and seventythree patients (63.8%) received adjuvant radiation therapy; this was associated with lower IR frequency (P = .048) but was not associated with reconstruction type (tissue expander versus autologous, P = 1.0) among 175 patients who had IR. In patients who have mastectomy after NAC, IR is influenced by age, T-stage at presentation, and choice of bilateral mastectomy, but not by response to NAC. A subset of patients who are young, with earlier T-stage and pCR, is more likely to proceed with bilateral mastectomy.
| INTRODUCTION
Neo-adjuvant systemic therapy for breast cancer is administered prior to surgical management to achieve a number of clinical goals. 1, 2 For patients with large tumors at presentation, neo-adjuvant chemotherapy (NAC) may allow for downstaging of the primary site, permitting consideration for breast-conservation surgery (BCS) if adequate response is achieved. [3] [4] [5] The rates of BCS are higher in women who receive neo-adjuvant therapy when compared to those who do not, adjusting for stage at presentation. 6 Additionally, in an era of evolving regional node management, patients who present with axillary node metastases and subsequently convert to clinically node negative after NAC may be staged with sentinel lymph node biopsy. The morbidity of an axillary lymph node dissection can be avoided if a complete pathologic response is achieved in the axillary nodes. [7] [8] [9] [10] [11] [12] The response to NAC is also an important prognostic indicator that allows for an assessment of tumor response during treatment. 13 The response to NAC is largely influenced by the histologic subtype of breast cancer. Patients with hormone receptor negative, HER2 positive breast cancers have the highest rate of pathologic complete response (pCR), ranging from 33-45%, while patients with hormone receptor positive, HER2 negative tumors have the lowest rate of pCR (15-23%). 14, 15 Patients receiving NAC may undergo mastectomy with or without reconstruction, either because of inadequate downstaging, as a planned procedure, or because of patient preference. NAC has been established as a valuable treatment strategy in the management of breast cancer. However, the extent to which response to NAC influences the choice for immediate reconstruction (IR) after mastectomy is not known. Here, we sought to determine the impact of response to NAC on breast reconstruction. Contraindications to BCS included tumor to breast size ratio, multicentric disease, inflammatory breast cancer, and progression during treatment. Of the 101 patients who were candidates for BCS after NAC, the most common reason for choosing mastectomy was patient preference (64 patients), followed by high genetic or familial risk (25 patients) and positive or close margin after attempt at BCS (9 patients).
| ME TH ODS
The reason was not known for 3 patients.
One hundred and forty-five patients (53.5%) had unilateral mastectomy and 126 (46.5%) had bilateral mastectomy (Table 1) .
Patients who underwent bilateral mastectomy were more likely to have been candidates for BCS after NAC than were patients who had unilateral mastectomy (57.9% versus 19.3%, P<.001). In multivariable analysis, patients who were younger, those with lower Tstage, those with triple-negative subtype, and those with a pCR were more likely to undergo bilateral mastectomy (Table 2) . Patients who chose bilateral mastectomy were more likely to have a pCR when compared with those who underwent unilateral mastectomy (32.5% versus 20.0%, P = .026).
Overall, 175 patients (64.6%) had IR and 96 (35.4%) had no IR (Table 3) . On univariable analysis, younger age (P < .001), lower Tstage at presentation (P < .001), bilateral mastectomy (P < .001), and HR-negative tumor subtype (P = .006) were significantly associated with higher rates of IR (Table 3) . Neither residual palpable breast mass after NAC nor residual palpable lymphadenopathy were associated with frequency of IR (P = .790 and P = .698, respectively). In patients who had positive nodes after NAC, those with abnormal axillary lymph nodes by imaging prior to surgery had a lower rate of IR (52.2% compared with 71.2% for those without abnormal axillary nodes on imaging prior to surgery, P = .020). In contrast, a persistent breast abnormality on imaging after NAC was not significantly associated with IR (P = .372). 
| DISCUSSION
We found that response to NAC, as assessed by both clinical response and pCR, was not correlated with uptake of IR. Rather, the factors associated with reconstruction after NAC are younger age, early T-stage at presentation, and choice of bilateral mastectomy, even when controlling for response to NAC. These results demonstrate that the majority of women who receive NAC are candidates for breast reconstruction after mastectomy.
The overall rate of pCR in our study was 25.8%. However, as observed in other studies, the rate of nodal response was higher.
We noted significant axillary downstaging; 71.1% of patients who presented with axillary metastases converted to clinically node negative by the time of surgery. Considering final nodal pathology, the rate of conversion from node positive at presentation to pathologically node negative was 43.3%. Neither conversion from clinically node positive to clinically node negative nor pCR was associated with increased rates of IR.
Although overall response to NAC was not associated with IR, it was statistically associated with choice of bilateral mastectomy.
Patients with pCR were more likely to undergo bilateral mastectomy than those without pCR. It is likely that contralateral prophylactic mastectomy would have been discouraged in patients who still had significant disease after NAC.
Overall, the majority of patients who underwent mastectomy rather than BCS were not candidates for BCS based on tumor factors. The decision for contralateral prophylactic mastectomy in patients who underwent bilateral mastectomy was largely by patient choice.
The safety of IR after NAC has been well established in recent reports. In a retrospective study, Donker et al compared the shortterm surgical outcomes of 37 patients undergoing immediate breast reconstruction after NAC to 176 of those who did not receive NAC. The rate of short-term surgical complications, such as hematoma, seroma, wound infection, and implant loss, was not significantly different between the groups. 16 The rates of short-term complications in our patients were similar to those reported in this study. Other reports have similarly shown acceptable complication rates of immediate breast reconstruction after NAC, even when radiation therapy is also utilized. [17] [18] [19] [20] [21] In terms of oncologic outcomes, Prabhu et al showed that IR may delay time to post-mastectomy radiation in patients treated with neo-adjuvant chemotherapy, but that there were no differences in locoregional control, disease-specific survival, and overall survival when compared to a cohort of patients who did not have breast reconstruction. 20 Similarly, the study by Gouy et al also demonstrated equivalent oncologic outcomes in patients treated with IR when compared to those who underwent mastectomy alone after NAC. 22 In that study, IR did not delay the start of adjuvant radiation therapy. In our study, patients who underwent IR received the first dose of radiation at a median of 60 days after surgery, while those who did not have IR received the first dose of radiation at a median of 47 days.
The absolute rate of IR in our population was slightly lower in patients who received adjuvant breast irradiation than in those who did not (60.1% versus 72.4%). This is consistent with a study of locoregional management after NAC in the American College of Surgeons Oncology Group (ACOSOG) Z1071 trial that demonstrated that patients who had reconstruction were statistically less likely to receive adjuvant radiation therapy. Differences between that analysis and our study included a larger number of patients (685) and, more importantly, all patients in that study had clinically node-positive disease. Therefore, the overall rate of adjuvant radiation was higher than in our study.
Our study is limited by its retrospective nature and the inability to fully capture the many factors that contribute to individual patient and surgeon decision making. Because our study was limited to only patients who were having a mastectomy after NAC, the impact of response to NAC on surgical treatment is limited. Further, it represents data collected at a designated cancer center with a highvolume breast surgery oncology practice. We noted a significant benefit to using NAC in our study, including axillary downstaging. Our study suggests that age and primary T-stage at presentation are predictors of IR in patients who are having a mastectomy after NAC. The response to NAC was not associated with a decision to undergo IR. In the patients who had IR, the complications were low and IR did not significantly delay radiation therapy administration. Additionally, age, Tstage at presentation, and pCR to NAC did influence the decision to proceed with bilateral mastectomy. Once the decision to proceed with a unilateral mastectomy was made, patients with a pCR were more likely to have a bilateral mastectomy and undergo IR.
In conclusion, for patients who need or choose a mastectomy after NAC, IR can be safely recommended. The response to NAC did not appear to be a factor in the decision to proceed with IR. 
T A B L E 4

